Abd Moain Abu Dabrh1, Khaled Mohammed, Noor Asi, Wigdan H Farah, Zhen Wang, Magdoleen H Farah, Larry J Prokop, Laurence Katznelson, Mohammad Hassan Murad. 1. Division of Preventive, Occupational, and Aerospace Medicine (A.M.A.D., M.H.M.), Mayo Clinic, Rochester Minnesota 55905, Knowledge and Evaluation Research Unit (A.M.A.D., K.M., N.A., W.H.F., Z.W., M.H.F., M.H.M.), Center for the Science of Health Care Delivery, Mayo Clinic, Rochester Minnesota 55905, Library Public Services (L.J.P.), Mayo Clinic, Rochester Minnesota 55905, and Department of Medicine, Division of Endocrinology and Metabolism and Department of Neurosurgery (L.K.), Stanford University School of Medicine, Stanford, California 94305.
Abstract
CONTEXT: Acromegaly is usually treated with surgery as a first-line treatment, although medical therapy has also been used as an alternative primary treatment. OBJECTIVE: We conducted a systematic review and meta-analysis to synthesize the existing evidence comparing these two approaches in treatment-naïve patients with acromegaly. DATA SOURCES: This study performed a comprehensive search in multiple databases, including Medline, EMBASE, and Scopus from early inception through April 2014. STUDY SELECTION: The study used original controlled and uncontrolled studies that enrolled patients with acromegaly to receive either surgical treatment or medical treatment as their first-line treatment. DATA EXTRACTION: Reviewers extracted data independently and in duplicates. Because of the noncomparative nature of the available studies, we modified the Newcastle-Ottawa Scale to assess the quality of included studies. Outcomes evaluated were biochemical remission and change in IGF-1 or GH levels. We pooled outcomes using the random-effects model. DATA SYNTHESIS: The final search yielded 35 studies enrolling 2629 patients. Studies were noncomparative series with a follow-up range of 6-360 months. Compared with medical therapy, surgery was associated with a higher remission rate (67% vs 45%; P = .02). Surgery had higher remission rates at longer follow-up periods (≥ 24 mo) (66% vs 44%; P = .04) but not the shorter follow-up periods (≤ 6 mo) (37% vs 26%; P = .22) [Corrected].Surgery had higher remission rates in the follow-up levels of GH (65% vs 46%; P = .05). In one study, the IGF-1 level was reduced more with surgery compared with medical treatment (-731 μg/L vs -251 μg/L; P = .04). Studies in which surgery was performed by a single operator reported a higher remission rate than those with multiple operators (71% vs 47%; P = .002). CONCLUSIONS: Surgery may be associated with higher remission rate; however, the confidence in such evidence is very low due to the noncomparative nature of the studies, high heterogeneity, and imprecision.
CONTEXT: Acromegaly is usually treated with surgery as a first-line treatment, although medical therapy has also been used as an alternative primary treatment. OBJECTIVE: We conducted a systematic review and meta-analysis to synthesize the existing evidence comparing these two approaches in treatment-naïve patients with acromegaly. DATA SOURCES: This study performed a comprehensive search in multiple databases, including Medline, EMBASE, and Scopus from early inception through April 2014. STUDY SELECTION: The study used original controlled and uncontrolled studies that enrolled patients with acromegaly to receive either surgical treatment or medical treatment as their first-line treatment. DATA EXTRACTION: Reviewers extracted data independently and in duplicates. Because of the noncomparative nature of the available studies, we modified the Newcastle-Ottawa Scale to assess the quality of included studies. Outcomes evaluated were biochemical remission and change in IGF-1 or GH levels. We pooled outcomes using the random-effects model. DATA SYNTHESIS: The final search yielded 35 studies enrolling 2629 patients. Studies were noncomparative series with a follow-up range of 6-360 months. Compared with medical therapy, surgery was associated with a higher remission rate (67% vs 45%; P = .02). Surgery had higher remission rates at longer follow-up periods (≥ 24 mo) (66% vs 44%; P = .04) but not the shorter follow-up periods (≤ 6 mo) (37% vs 26%; P = .22) [Corrected].Surgery had higher remission rates in the follow-up levels of GH (65% vs 46%; P = .05). In one study, the IGF-1 level was reduced more with surgery compared with medical treatment (-731 μg/L vs -251 μg/L; P = .04). Studies in which surgery was performed by a single operator reported a higher remission rate than those with multiple operators (71% vs 47%; P = .002). CONCLUSIONS: Surgery may be associated with higher remission rate; however, the confidence in such evidence is very low due to the noncomparative nature of the studies, high heterogeneity, and imprecision.
Authors: Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller Journal: Endocr Pract Date: 2011 Jul-Aug Impact factor: 3.443
Authors: A Bałdys-Waligórska; A Krzentowska-Korek; F Gołkowski; G Sokołowski; A Hubalewska-Dydejczyk Journal: Exp Clin Endocrinol Diabetes Date: 2011-01-24 Impact factor: 2.949
Authors: John A Jane; Robert M Starke; Mohamed A Elzoghby; Davis L Reames; Spencer C Payne; Michael O Thorner; John C Marshall; Edward R Laws; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06-29 Impact factor: 5.958
Authors: S Grottoli; R Celleno; V Gasco; R Pivonello; D Caramella; A Barreca; F Ragazzoni; F Pigliaru; D Alberti; R Ferrara; G Angeletti Journal: J Endocrinol Invest Date: 2005-12 Impact factor: 4.256
Authors: Amit Tirosh; Georgios Z Papadakis; Prashant Chittiboina; Charalampos Lyssikatos; Elena Belyavskaya; Meg Keil; Maya B Lodish; Constantine A Stratakis Journal: Horm Metab Res Date: 2017-05-04 Impact factor: 2.936
Authors: T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu Journal: J Endocrinol Invest Date: 2016-10-20 Impact factor: 4.256
Authors: Emmanuelle Kuhn; Luigi Maione; Amir Bouchachi; Myriam Rozière; Sylvie Salenave; Sylvie Brailly-Tabard; Jacques Young; Peter Kamenicky; Patrick Assayag; Philippe Chanson Journal: Eur J Endocrinol Date: 2015-11 Impact factor: 6.664